JP2020529413A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529413A5 JP2020529413A5 JP2020505232A JP2020505232A JP2020529413A5 JP 2020529413 A5 JP2020529413 A5 JP 2020529413A5 JP 2020505232 A JP2020505232 A JP 2020505232A JP 2020505232 A JP2020505232 A JP 2020505232A JP 2020529413 A5 JP2020529413 A5 JP 2020529413A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- salt
- acceptable salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 55
- 150000003839 salts Chemical class 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- -1 Y is H Chemical group 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 101001117044 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Proteins 0.000 description 1
- 101001117099 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B Proteins 0.000 description 1
- 101001117094 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C Proteins 0.000 description 1
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 1
- 101001098818 Homo sapiens cGMP-inhibited 3',5'-cyclic phosphodiesterase A Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 102000055551 human PDE1A Human genes 0.000 description 1
- 102000055462 human PDE1B Human genes 0.000 description 1
- 102000055048 human PDE1C Human genes 0.000 description 1
- 102000055047 human PDE3A Human genes 0.000 description 1
- 102000048135 human PDE4D Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540122P | 2017-08-02 | 2017-08-02 | |
| US62/540,122 | 2017-08-02 | ||
| PCT/US2018/043845 WO2019027783A1 (en) | 2017-08-02 | 2018-07-26 | DERIVATIVES OF [1,2,4] TRIAZOLO [4,3-A] PYRAZIN-6 (5H) -ONE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529413A JP2020529413A (ja) | 2020-10-08 |
| JP2020529413A5 true JP2020529413A5 (enExample) | 2020-11-19 |
| JP6850396B2 JP6850396B2 (ja) | 2021-03-31 |
Family
ID=63165529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505232A Active JP6850396B2 (ja) | 2017-08-02 | 2018-07-26 | ［１，２，４］トリアゾロ［４，３−ａ］ピラジン−６（５ｈ）−オン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11180503B2 (enExample) |
| EP (1) | EP3661936B1 (enExample) |
| JP (1) | JP6850396B2 (enExample) |
| CN (1) | CN110914268B (enExample) |
| AR (1) | AR112457A1 (enExample) |
| ES (1) | ES2904938T3 (enExample) |
| TW (1) | TWI670271B (enExample) |
| WO (1) | WO2019027783A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11453673B2 (en) | 2018-02-06 | 2022-09-27 | Eli Lilly And Company | Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors |
| WO2025059641A1 (en) | 2023-09-14 | 2025-03-20 | Eli Lilly And Company | Pde1 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4354027A (en) | 1980-05-19 | 1982-10-12 | Usv Pharmaceutical Corporation | Triazoloquinoxalin-4-ones |
| AU2007260851B2 (en) * | 2006-06-23 | 2013-01-17 | Incyte Corporation | Purinone derivatives as HM74a agonists |
| CA2671980C (en) * | 2006-12-13 | 2015-05-05 | Aska Pharmaceutical Co., Ltd. | Quinoxaline derivatives |
| WO2008103357A1 (en) | 2007-02-21 | 2008-08-28 | E. I. Du Pont De Nemours And Company | Fungicidal tricyclic 1,2,4-triazoles |
| WO2011060207A1 (en) * | 2009-11-16 | 2011-05-19 | Schering Corporation | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY |
| JP5822080B2 (ja) | 2010-09-07 | 2015-11-24 | アステラス製薬株式会社 | キノキサリン化合物 |
| CN103874701A (zh) * | 2011-09-09 | 2014-06-18 | H.隆德贝克有限公司 | 吡啶化合物和其用途 |
| AU2013277294C1 (en) | 2012-06-18 | 2018-02-08 | Dart Neuroscience (Cayman) Ltd | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
| US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| TW201629064A (zh) * | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| TWI609870B (zh) * | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1抑制劑 |
| JOP20170164A1 (ar) * | 2016-08-25 | 2019-01-30 | Lilly Co Eli | مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري |
-
2018
- 2018-07-17 AR ARP180101984 patent/AR112457A1/es unknown
- 2018-07-19 TW TW107124931A patent/TWI670271B/zh not_active IP Right Cessation
- 2018-07-26 JP JP2020505232A patent/JP6850396B2/ja active Active
- 2018-07-26 CN CN201880050277.1A patent/CN110914268B/zh active Active
- 2018-07-26 ES ES18752976T patent/ES2904938T3/es active Active
- 2018-07-26 US US16/624,545 patent/US11180503B2/en active Active
- 2018-07-26 WO PCT/US2018/043845 patent/WO2019027783A1/en not_active Ceased
- 2018-07-26 EP EP18752976.3A patent/EP3661936B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522879A5 (enExample) | ||
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2020507589A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| RU2015143841A (ru) | Ингибиторы hdac | |
| JP2017531619A5 (enExample) | ||
| JP2020532547A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2016518324A5 (enExample) | ||
| RU2015143610A (ru) | Лечение катаплексии | |
| JP2017517565A5 (enExample) | ||
| JP2016501221A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2014501766A5 (enExample) | ||
| JP2019510034A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2019501879A5 (enExample) | ||
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| JP2016515628A5 (enExample) | ||
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| JP2019510027A5 (enExample) | ||
| JP2020532545A5 (enExample) | ||
| JP2016522254A5 (enExample) | ||
| JP2010521516A5 (enExample) | ||
| JP2014512355A5 (enExample) |